FDA broadly supports Oragenics’ Pre-IND development programme for SARS-CoV-2 vaccine

This article was originally published here

As a result, the Company believes its timelines for both filing an Investigational New Drug (“IND”) application and the commencement of the Phase 1 study will proceed on

The post FDA broadly supports Oragenics’ Pre-IND development programme for SARS-CoV-2 vaccine appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply